Target-led treatments for lung cancer – are they moving to the next level?
Antibody–drug conjugates may represent a step up from existing therapeutic options, but further optimisation and biomarker analyses are required.
Technology integration and access to eligible patients underpin the growth of early-phase trials in Asia Pacific
Global cooperation is needed to improve trial design and expedite new treatments specifically in low- and middle-income countries
ctDNA and RNA-based tests are expanding colorectal cancer screening options
The availability of simpler, less-invasive methodologies may help to encourage participation in secondary prevention programmes
Decoding genomic and transcriptomic signatures in colorectal cancer – next steps?
Newer technologies build on current knowledge to provide greater insights in the molecular landscape
Advancing perioperative treatment in resectable non-small cell lung cancer
Findings from the NeoADAURA and the CheckMate 816 provide novel insights on the role of neoadjuvant osimertinib and nivolumab in the perioperative setting
Early data presented for a biomarker-guided care of metastatic hormone-sensitive prostate cancer
Positive findings from the CAPTURE and AMPLITUDE trials highlight the importance of early testing patients for BRCA and HRR mutations
Challenging ageism in gynaecological cancers
Recent research indicates that older age remains a barrier to accessing optimal treatment, despite a growing number of patients over 70 with ovarian and endometrial tumours
The emerging era of liquid biopsy in endocrine-resistant metastatic breast cancer
Novel evidence demonstrates the clinical utility of circulating tumour DNA in patients with HR+/HER2- cancers harbouring ESR1 and PIK3CA mutations
First-line use of antibody-drug conjugates: a turning point in metastatic breast cancer
Findings from recently presented studies support an upfront integration of ADCs in the treatment course, but some key questions are pending
New evidence is reshaping second-line and maintenance treatment for small cell lung cancer
Two studies investigating efficacy of bispecific T-cell engager tarlatamab and lurbinectedin–atezolizumab combination met their primary endpoints of survival